Glenmark Pharmaceuticals Limited

BSE: 532296 NSE: GLENMARK
Glenmark Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24299MH1977PLC019982 Incorporated 18 November 1977 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: GLENMARK · BSE: 532296 Public Limited Company pharma Fortune India 500 · #201 Nifty 500
Data last updated
Market Cap
₹64,912 Cr
GLENMARK · NSE
Share Price
₹2,339.00
+1.70% today
Revenue
₹16,983 Cr
FY 2025-26 · +27.5% YoY
EBITDA
₹2,306 Cr
Margin 13.6%
Net Profit
₹2,281 Cr
FY 2025-26 · +73.0% YoY
P/E (TTM)
20.5x
P/B 6.1x
ROE
23.6%
ROCE 35.1%
Debt / Equity
0.16
Interest cover 12.1x

About Glenmark Pharmaceuticals Limited

Data last updated:

Glenmark Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 November 1977 and has been in existence for over 49 years.

Glenmark Pharmaceuticals is ranked #201 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Glenn Saldanha and family are #99 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24299MH1977PLC019982. Its GSTIN is 27AAACG2207L1ZS (Maharashtra). The company holds 32 GST registrations, of which 12 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532296 and NSE: GLENMARK.

The company has an authorised share capital of ₹277 Cr and a paid-up capital of ₹28.22 Cr. It was formerly known as Glenmark Pharmaceuticals Private Limited. It is led by directors including Glenn Mario Saldanha (Managing Director) and Cherylann Maria Pinto (Whole-Time Director).

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at B – 2 Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India – 400026.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹16,983 Cr, a growth of 27.5% compared to the previous year. For the same year it recorded a net profit of ₹2,280.62 Cr (net margin 13.4%) and EBITDA of ₹2,306.34 Cr (EBITDA margin 13.6%). The net worth stands at ₹10,512 Cr (up 18.8% YoY). Total assets are valued at ₹13,637 Cr (up 15.6% YoY).

The company has about 13,458 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Glenmark Pharmaceuticals. As per MCA filings, the company has open charges of ₹890 Cr and satisfied charges of ₹1,040 Cr on record. Court records list 416 cases involving the company, including 306 filed by the company and 110 filed against it; 120 cases are pending. The company has 42 deals on record (29 market trades, 5 acquisitions, 4 secondary share transfers), with disclosed funding of ₹1,697.92 Cr; the latest was in July 2025. Its 9 peer companies in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Lupin Limited with revenue of ₹22,904 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 188 overdue payments to 6 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glenmarkpharma.com.

Company details

CIN L24299MH1977PLC019982
Registration Number 019982
Incorporation Date 18 November 1977
ROC Mumbai
Listing Status Listed - Listed on NSE (GLENMARK); Listed on BSE (532296)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Glenn Mario Saldanha Managing Director Cherylann Maria Pinto Whole-Time Director Anurag Mantri Whole-Time Director

Recognitions & Rankings of Glenmark Pharmaceuticals

Fortune India 500 2025 edition
Rank#201
Total income
₹13,649 Cr
Profit
₹1,047 Cr
Last year #188
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#144
Valuation
₹42,720 Cr
2023 #206 2022 #298 2021 #253
Stock market indices
Nifty 500 BSE 500

Contact details

Glenmark Pharmaceuticals Limited's registered office is in Mumbai, Maharashtra. Its website is glenmarkpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    glenmarkpharma.com
  • Social Media
  • Registered Address
    B – 2 Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India – 400026
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers

To see the full contact details of Glenmark Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Glenmark Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Glenmark Pharmaceuticals operates one associated brand: Glenmark Pharmaceuticals. Each brand links to its own profile.

BrandDescriptionWebsite
Glenmark Pharmaceuticals
R&D company focused on manufacturing generic drugs for multiple therapeutic areasglenmarkpharma.com

Business activity

The main business activity of Glenmark Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Glenmark Pharmaceuticals Limited, buy the company report.

Financials of Glenmark Pharmaceuticals Limited

FY 2025-26 filings available

Glenmark Pharmaceuticals Limited reported revenue of ₹16,983 Cr (up 27.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹16,983 Cr
+27.5% YoY
EBITDA
₹2,306 Cr
+16.6% YoY
Profit After Tax
₹2,281 Cr
+73.0% YoY
Net Worth
₹10,512 Cr
+18.8% YoY
Total Assets
₹13,637 Cr
+15.6% YoY
Total Debt
₹594 Cr
-76.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16,98313,32211,81311,58312,30510,94410,641
Revenue growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
EBITDA2,3061,9792948692,0592,0841,698
EBITDA margin+13.6%+14.9%+2.5%+7.5%+16.7%+19.1%+16.0%
Profit before tax1,9851,3994347071,4411,3821,096
Net profit2,2811,318(4,474)6101,108941756
Net profit margin+13.4%+9.9%-37.9%+5.3%+9.0%+8.6%+7.1%
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
Balance sheet
Total assets13,63711,7989,61914,84513,55312,24711,368
Net worth10,5128,8497,8489,4749,0877,0656,071
Total debt5942,4731,2314,6083,9624,9864,869
Cash & bank1,1761,7051,6591,1601,4121,1391,111
Net working capital5,0305,1022,6896,1994,7834,0313,503
Cash flow
Cash from operations3,445(828)(265)6251,1091,1311,392
Cash from investing(1,237)57.994,387(515)(316)(662)(774)
Cash from financing(2,709)787(3,906)(77.46)(520)(442)(445)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0183,7713,9016,0473,2643,2563,3883,434
Revenue growth (YoY)+23.1%+15.8%+15.2%+76.1%+0.6%---
Other income65.7618944.4720126.4411.6931.1339.42
EBITDA805389685974257188600602
EBITDA margin+20.5%+10.4%+17.6%+16.2%+8.4%+5.8%+18.2%+17.7%
Depreciation173148154141130125123120
Interest54.0042.6041.4366.4658.2366.7152.2948.48
Profit before tax64338853496795.577.97456473
Tax16186.4513135748.603.59108118
Net profit48330140361046.974.38348354
EPS (₹)17.1110.6814.2821.621.660.1612.3312.55
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue8,4409,2267,8918,2218,1427,5686,713
Revenue growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
EBITDA(723)2,0651,2429771,6881,8901,304
EBITDA margin-8.6%+22.4%+15.7%+11.9%+20.7%+25.0%+19.4%
Profit before tax(266)2,1547,0011,5722,3371,9441,535
Net profit9421,7631,4251,5781,6441,5901,340
Net profit margin+11.2%+19.1%+18.1%+19.2%+20.2%+21.0%+20.0%
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
Balance sheet
Total assets25,84825,46623,81021,47120,59818,65017,006
Net worth24,15024,50422,97117,87716,73914,81013,226
Total debt1078307073,2213,7383,7043,574
Cash & bank29313312993.7929.6315.7988.26
Net working capital2,4582,2681,0771,2712,0862,9422,478
Cash flow
Cash from operations543589(495)1,4741,2161,2431,579
Cash from investing569(490)3,197(432)(897)(1,235)(1,607)
Cash from financing(952)(95.41)(2,666)(978)(305)(80.79)(139)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,4352,1472,3601,5392,3952,0102,2512,636
Revenue growth (YoY)+1.7%+6.8%+4.8%-41.6%+2.8%---
Other income33830810928669.3488.4512983.08
Total expenses1,8222,4842,0412,6481,9901,8481,7571,857
EBITDA613(337)319(1,110)405161494779
EBITDA margin+26.2%-15.3%+13.7%-91.0%+18.6%+8.4%+22.4%+30.0%
Depreciation62.3260.1359.1858.9357.6455.5355.1654.85
Interest23.2517.9121.9823.4015.4613.138.4611.80
Profit before tax866(107)347(906)401181560795
Tax130(33.50)64.46(167)70.9433.40146200

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0183,7713,9016,0473,2643,2563,3883,434
Revenue growth (YoY)+23.1%+15.8%+15.2%+76.1%+0.6%---
Other income65.7618944.4720126.4411.6931.1339.42
EBITDA805389685974257188600602
EBITDA margin+20.5%+10.4%+17.6%+16.2%+8.4%+5.8%+18.2%+17.7%
Depreciation173148154141130125123120
Interest54.0042.6041.4366.4658.2366.7152.2948.48
Profit before tax64338853496795.577.97456473
Tax16186.4513135748.603.59108118
Net profit48330140361046.974.38348354
EPS (₹)17.1110.6814.2821.621.660.1612.3312.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16,98313,32211,81311,58312,30510,94410,641
Revenue growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
Other income4611141,23775616794.76192
Total expenses14,67611,34311,51910,71410,2468,8608,943
Employee cost3,5783,0222,8682,6012,4472,3442,255
EBITDA2,3061,9792948692,0592,0841,698
EBITDA margin+13.6%+14.9%+2.5%+7.5%+16.7%+19.1%+16.0%
Depreciation573486582569487444417
Interest209207516349298353377
Profit before tax1,9851,3994347071,4411,3821,096
Tax6233521,867329448412320
Net profit2,2811,318(4,474)6101,108941756
Net profit margin+13.4%+9.9%-37.9%+5.3%+9.0%+8.6%+7.1%
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital28.2228.2228.2228.2228.2228.2228.22
Reserves & surplus10,4848,8217,8209,4469,0587,0366,042
Shareholders' funds (net worth)10,5128,8497,8489,4749,0877,0656,071
Minority interest(0.32)(0.37)(0.38)365351(0.35)(0.39)
Secured loans0.002991570.000.000.000.00
Unsecured loans5942,1741,0744,6083,9624,9864,869
Total debt5942,4731,2314,6083,9624,9864,869
Total liabilities13,63711,7989,61914,84513,55312,24711,368
Assets
Gross block12,07210,3659,62010,36010,2138,7328,270
Net block5,9154,4874,2105,4225,8875,1295,029
Capital work in progress9098356621,1901,0101,3821,222
Investments42.3656.3679044.5749.6224.6324.59
Inventories3,4313,0292,5132,3742,5002,2772,136
Sundry debtors4,9633,3421,8583,6653,1012,5722,409
Cash & bank balances1,1761,7051,6591,1601,4121,1391,111
Loans & advances1,7291,2201,3973,5261,2701,3721,148
Total current assets11,3009,2957,42810,7268,2827,3606,804
Total current liabilities6,2694,1934,7394,5263,4993,3283,300
Net working capital5,0305,1022,6896,1994,7834,0313,503
Total assets13,63711,7989,61914,84513,55312,24711,368
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,6761,6581,4431,4111,1381,110936
Net cash from operating activities3,445(828)(265)6251,1091,1311,392
Net cash from investing activities(1,237)57.994,387(515)(316)(662)(774)
Net cash from financing activities(2,709)787(3,906)(77.46)(520)(442)(445)
Net change in cash(501)17.4421532.5027227.82174
Closing cash1,1761,7051,6591,1601,4121,1391,111
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
EBITDA growth+16.6%+572.1%-66.1%-57.8%-1.2%+22.8%-
PBT growth+41.9%+222.5%-38.6%-51.0%+4.3%+26.1%-15.7%
Net income growth+73.0%+129.5%-833.8%-45.0%+17.7%+24.6%-
Revenue CAGR (3Y)+13.6%+2.7%+2.6%+2.9%+7.6%+6.4%+5.4%
EBITDA CAGR (3Y)+38.4%-1.3%-47.9%-20.0%+9.1%+8.9%-4.6%
Profitability & leverage
Net income margin+8.0%+7.9%-12.1%+3.3%+8.1%+8.9%+7.3%
Return on capital employed+35.1%+18.5%+12.1%+9.8%+15.8%+14.7%+13.7%
Return on net worth+23.6%+15.8%-50.9%+7.4%+14.4%+14.8%+13.3%
Debt / equity0.160.220.340.460.550.750.80
Long-term debt / equity0.060.050.240.370.430.620.65
Interest cover12.0513.87-179.45116.3518.9621.5229.46
Efficiency & per share
Fixed asset turnover1.511.331.181.131.301.291.44
Inventory turnover5.264.814.834.755.154.964.85
Debtors turnover4.095.124.283.424.344.394.62
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
Dividend per share (₹)5.002.502.502.502.502.502.50
Book value per share (₹)372.51313.60278.11335.75322.03250.37215.14
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,4352,1472,3601,5392,3952,0102,2512,636
Revenue growth (YoY)+1.7%+6.8%+4.8%-41.6%+2.8%---
Other income33830810928669.3488.4512983.08
Total expenses1,8222,4842,0412,6481,9901,8481,7571,857
EBITDA613(337)319(1,110)405161494779
EBITDA margin+26.2%-15.3%+13.7%-91.0%+18.6%+8.4%+22.4%+30.0%
Depreciation62.3260.1359.1858.9357.6455.5355.1654.85
Interest23.2517.9121.9823.4015.4613.138.4611.80
Profit before tax866(107)347(906)401181560795
Tax130(33.50)64.46(167)70.9433.40146200
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue8,4409,2267,8918,2218,1427,5686,713
Revenue growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
Other income7723566,2389861,045470625
Total expenses9,1647,1616,6497,2446,4535,6785,408
Employee cost1,7901,6041,4351,3471,1931,1071,072
EBITDA(723)2,0651,2429771,6881,8901,304
EBITDA margin-8.6%+22.4%+15.7%+11.9%+20.7%+25.0%+19.4%
Depreciation236219202184160151139
Interest78.7548.73277207236266256
Profit before tax(266)2,1547,0011,5722,3371,9441,535
Tax(65.27)5441,833363340294180
Net profit9421,7631,4251,5781,6441,5901,340
Net profit margin+11.2%+19.1%+18.1%+19.2%+20.2%+21.0%+20.0%
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital28.2228.2228.2228.2228.2228.2228.22
Reserves & surplus24,12224,47622,94217,84916,71014,78113,198
Shareholders' funds (net worth)24,15024,50422,97117,87716,73914,81013,226
Secured loans0.002990.000.000.000.000.00
Unsecured loans1075317073,2213,7383,7043,574
Total debt1078307073,2213,7383,7043,574
Total liabilities25,84825,46623,81021,47120,59818,65017,006
Assets
Gross block4,0163,7433,3933,1843,0262,8492,595
Net block2,0281,9791,7561,7461,7521,7221,612
Capital work in progress159155198172109131200
Investments15,20215,19512,96510,3348,5596,9904,714
Inventories1,2881,3691,1431,090952762838
Sundry debtors3,3062,5502,4842,5062,6782,4891,835
Cash & bank balances29313312993.7929.6315.7988.26
Loans & advances1,2087259256967431,6421,663
Total current assets6,0954,7784,6814,3854,4034,9094,424
Total current liabilities3,6372,5093,6053,1152,3171,9671,946
Net working capital2,4582,2681,0771,2712,0862,9422,478
Total assets25,84825,46623,81021,47120,59818,65017,006
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash13112892.7028.6514.7287.29255
Net cash from operating activities543589(495)1,4741,2161,2431,579
Net cash from investing activities569(490)3,197(432)(897)(1,235)(1,607)
Net cash from financing activities(952)(95.41)(2,666)(978)(305)(80.79)(139)
Net change in cash1603.4935.2764.0513.93(72.57)(168)
Closing cash29313312993.7929.6315.7988.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
EBITDA growth-135.0%+66.3%+27.1%-42.1%-10.7%+44.9%-
PBT growth--69.2%+345.4%-32.8%+20.3%+26.7%-21.4%
Net income growth-46.6%+23.7%-9.7%-4.0%+3.4%+18.6%-
Revenue CAGR (3Y)+0.9%+4.3%+1.4%+7.0%+8.9%+11.1%-5.6%
EBITDA CAGR (3Y)-+7.0%-13.1%-9.2%+8.3%+19.7%-21.2%
Profitability & leverage
Net income margin-2.4%+17.5%+65.5%+14.7%+24.5%+21.8%+20.2%
Return on capital employed+6.3%+8.9%+9.8%+10.8%+10.9%+12.4%+11.1%
Return on net worth+3.9%+6.8%+7.0%+9.1%+10.4%+11.8%+10.8%
Debt / equity0.020.030.100.200.240.260.27
Long-term debt / equity0.000.000.070.150.180.220.24
Interest cover-8.212.6426.6626.0915.4415.2921.99
Efficiency & per share
Fixed asset turnover2.182.592.402.652.772.782.77
Inventory turnover6.357.357.078.059.509.467.68
Debtors turnover2.883.673.163.173.153.503.42
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
Dividend per share (₹)5.002.502.502.502.502.502.50
Book value per share (₹)855.79868.35814.01633.57593.21524.84468.73

To see the full year-wise statements and ratios of Glenmark Pharmaceuticals Limited, buy the company report.

Board of directors of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has 9 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sona Saira RamasastryDirector01 Apr 20197 Years 6 MonthsCurrent
Glenn Mario Saldanha
Also directs: Glenmark Healthcare Limited, Glenmark Consumer Care Limited
Managing Director12 Oct 199828 Years 0 MonthsCurrent
Blanche Saldanha ElizabethDirector14 Aug 200917 Years 2 MonthsCurrent
Cherylann Maria Pinto
Also directs: Glenmark Healthcare Limited
Whole-Time Director16 May 200719 Years 5 MonthsCurrent
Dipankar BhattacharjeeDirector14 Aug 20206 Years 2 MonthsCurrent
Vijayalakshmi Iyer
Also directs: Icici Bank Limited, Computer Age Management Services Limited, CG Power and Industrial Solutions Limited and 5 more
Director10 Feb 20233 Years 8 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Glenmark Pharmaceuticals Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Glenmark Pharmaceuticals Limitedthis company₹16,983 Cr (FY 2026)₹2,280.62 Cr13.4%27.5%13,458Mumbai, Maharashtra, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Biocon Limited₹16,470 Cr (FY 2025)5.0%Bengaluru, Karnataka, India
Alkem Laboratories Limited₹13,458 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Torrent Pharmaceuticals Ltd₹11,539 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Serum Institute of India Private Limited₹10,854 Cr (FY 2025)-2.0%Pune, Maharashtra, India
Biocon Biologics Limited₹10,144 Cr (FY 2025)13.0%Bengaluru, Karnataka, India
Divi's Laboratories Limited₹9,712 Cr (FY 2025)19.0%Hyderabad, Telangana, India

To see the full peer comparison of Glenmark Pharmaceuticals Limited, buy the company report.

Auditor

Glenmark Pharmaceuticals Limited is audited by Suresh Surana & Associates LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Suresh Surana & Associates LLPFY 2024121750W/W-100010

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 46.60%, foreign institutional investors hold 20.90%, domestic institutional investors hold 18.60% and retail and other public shareholders hold 13.90%.

Promoters: 46.60%DII (Domestic Institutional): 18.60%FII (Foreign Institutional): 20.90%Retail & Others: 13.90%
Sep 2026
QUARTER
46.60% Promoters
18.60% DII (Domestic Institutional)
20.90% FII (Foreign Institutional)
13.90% Retail & Others
Promoter holding - history
Now 46.60% · Sep 2026High 46.60% · Dec 2025Low 46.60% · Dec 2025
45%45.8%46.5%47.3%48%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 46.60%Mar 2026: 46.60%Jun 2026: 46.60%Sep 2026: 46.60%46.60%46.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters46.60%46.60%46.60%46.60%
Public53.40%53.40%53.40%53.40%

Charges & borrowings

Open charges
₹890 Cr
Satisfied charges
₹1,040 Cr
Breakdown by lending institutions
Bank of India₹890.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
21 May 198580020353Bank of India₹890 CrOpen
29 Jul 200910172979Bank of India₹60 CrSatisfied
18 Jun 200910161795Axis Bank Limited₹75 CrSatisfied
16 Jan 200910141439Central Bank of India₹150 CrSatisfied
09 Jun 200810114486Bank of India₹170 CrSatisfied

To see the full charge records of Glenmark Pharmaceuticals Limited, buy the company report.

Total charge records: 14 View all charges

Deals & funding

Glenmark Pharmaceuticals Limited has 42 deals on record (29 market trades, 5 acquisitions, 4 secondary share transfers), with disclosed funding of ₹1,697.92 Cr; the latest was in July 2025.

Total deals
42
Market trades
29
Acquisitions
5
Secondary share transfers
4
Funding rounds
3
Disclosed funding
₹1,697.92 Cr

Deals on record (5 of 42)

WhenDealAmountParties
Jul 2025Market trade₹328.3 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jan 2023Acquisition₹340 CrBuyer: Eris Oaknet Healthcare Private Limited
Seller: Glenmark Pharmaceuticals Limited
Dec 2022Acquisition₹313.7 CrBuyer: J B Chemicals and Pharmaceuticals Limited
Seller: Glenmark Pharmaceuticals Limited
Nov 2020AcquisitionUndisclosedBuyer: Dr.Reddy's Laboratories Ltd
Seller: Glenmark Pharmaceuticals Limited
Jun 2020Market trade₹69.94 CrBuyer: Centillion Research India LLP
Seller: Centillion Research India LLP

To see the full deal history of Glenmark Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Glenmark Pharmaceuticals Limited was last rated by Crisil on 23 Jun 2020.

Rating agencyRated onRating
Crisil23 Jun 2020

To see the full credit ratings and regulatory alerts of Glenmark Pharmaceuticals Limited, buy the company report.

MSME payment delays

Glenmark Pharmaceuticals Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 188 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 6)

SupplierAmount dueDue sinceReported on
Acron Plast Private Limited
Alpha Chemicals Private Limited
Acacia Traders
Amkay Products Limited
Art in Art

To see the full MSME payment records of Glenmark Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Glenmark Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Glenmark Healthcare LimitedU21001MH2023PLC402796

To see the full group structure of Glenmark Pharmaceuticals Limited, buy the company report.

Employees & EPFO

Glenmark Pharmaceuticals Limited has a workforce of 13,458 employees on its EPFO records as of Mar 08, 2025, across 2 active EPFO establishments.

Employee count
13,458
Active EPFO establishments
2
Employee growth
8.3%

GST

Glenmark Pharmaceuticals has 32 GST registrations: 12 active and 20 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
32
Active
12
Cancelled / inactive
20
GSTINStateStatusRegistered on
27AAACG2207L1ZSMaharashtraActive01 Jul 2017
27AAACG2207L2ZRMaharashtraActive08 Jul 2017
02AAACG2207L2Z3Himachal PradeshActive01 Jul 2017
06AAACG2207L1ZWHaryanaActive01 Jul 2017

To see the full GST registrations and return filing status of Glenmark Pharmaceuticals Limited, buy the company report.

Recent activity

Glenmark Pharmaceuticals Limited has 41 board changes on record since 1977: 25 appointments and 16 cessations. The latest: Patricia Susan Andrews was appointed as Director on 14 Aug 2025.

Filing
Glenmark Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Glenmark Pharmaceuticals Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Appointed
Patricia Susan Andrews was appointed as Director.
Ceased
Rajesh Vasudeo Desai ceased to be Director.
Appointed
Anurag Mantri was appointed as Whole-Time Director.
Ceased
V S Mani ceased to be Whole-Time Director.
Appointed
Pradeep Kumar Sinha was appointed as Director.
Ceased
Bernard Hubert Munos ceased to be Director.
Ceased
Brian William Tempest ceased to be Director.
Ceased
Devendra Raj Mehta ceased to be Director.
Ceased
Sridhar Gorthi ceased to be Director.
Appointed
Vijayalakshmi Iyer was appointed as Director.

65 earlier events are in the company report.

News

Glenmark: Glenmark Therapeutics Inc., USA Introduces Pump Packs for Adapalene Gel USP With Annual Sales Around USD 45.8 Million
06 Oct 2026 · Exchange Update
Glenmark Pharma: Gets EIR From U.S. FDA For Goa Facility With VAI Status
23 Sep 2026 · Exchange Update
GLENMARK: Rs. 37.28 Crores NSE Block Trade; for ~ 150,735 Shares, at Rs. 2473.00
23 Sep 2026 · Exchange Update

From our blog

Frequently asked questions

Glenmark Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 November 1977 (49+ years old) and is registered under CIN L24299MH1977PLC019982. Listed on BSE: 532296 and NSE: GLENMARK.

Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr for FY 2025-26 (up 27.5% YoY) based on consolidated financials.

Glenmark Pharmaceuticals has 9 current directors:

The latest financial statements of Glenmark Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Glenmark Pharmaceuticals is 27AAACG2207L1ZS, registered in Maharashtra. The company has 32 GST registrations in all, of which 12 are active and 20 are cancelled or inactive. Other active GSTINs include 27AAACG2207L2ZR (Maharashtra), 02AAACG2207L2Z3 (Himachal Pradesh), 06AAACG2207L1ZW (Haryana).

The CIN (Corporate Identification Number) of Glenmark Pharmaceuticals is L24299MH1977PLC019982. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Glenmark Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 532296) and NSE (symbol: GLENMARK).

Glenmark Pharmaceuticals has 416 court cases on record: 306 filed by the company and 110 filed against it. 120 are pending. Most are in the high courts.

Glenmark Pharmaceuticals was incorporated on 18 November 1977, making it 49+ years old. It is registered with the Registrar of Companies, Mumbai.

Glenmark Pharmaceuticals has 42 deals on record (29 market trades, 5 acquisitions, 4 secondary share transfers), with disclosed funding of ₹1,697.92 Cr; the latest was in July 2025.

The peers of Glenmark Pharmaceuticals by revenue are Lupin Limited, Intas Pharmaceuticals Limited, Hetero Labs Limited, Biocon Limited, Alkem Laboratories Limited and 4 more, all in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Patricia Susan Andrews was appointed as Director on 14 Aug 2025. Rajesh Vasudeo Desai ceased to be Director on 25 Jun 2025. Anurag Mantri was appointed as Whole-Time Director on 27 May 2025. Glenmark Pharmaceuticals has 41 board changes on record in total.